Friday, 13 November 2026European Markets

Euro Surges 14% Against Dollar, Testing EU Export Competitiveness

The euro has appreciated 14% in 2025 as the US dollar hits its lowest level since 2022, creating new challenges for European exporters. The British pound gained 7% over the same period, though analysts at Mizuho Bank forecast potential weakness below $1.30. Safe-haven flows have pushed the Swiss franc higher amid shifting currency dynamics.

From our archive, published before source-traceability. How we work

Euro Surges 14% Against Dollar, Testing EU Export Competitiveness
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

The euro has jumped 14% against the US dollar in 2025, reaching its strongest position since 2022 as the greenback experiences significant weakness across major currency pairs.

The currency appreciation poses immediate challenges for EU exporters who compete globally on price. German manufacturers and French industrial producers face margin pressure as euro-denominated goods become more expensive for buyers using dollars or dollar-pegged currencies.

The British pound gained 7% against the dollar in the same timeframe, though Jordan Rochester at Mizuho Bank warns sterling could fall below $1.30 despite recent strength. The pound traded at $1.3086 this week, down 0.5% from previous levels.

Simon Phillips, Managing Director at No1 Currency, notes ongoing pressure on the pound. Against the euro, sterling fell 0.4% to €1.13, its weakest level since April 2023.

The Swiss franc has strengthened on safe-haven flows as investors reposition amid forex volatility. Currency analysts point to geopolitical developments including Iran nuclear negotiations and Japanese yen movements as additional factors reshaping exchange rate dynamics.

The European Central Bank faces a policy dilemma. A stronger euro acts as monetary tightening by reducing import costs and dampening inflation, potentially allowing rate cuts. But euro strength simultaneously hurts export competitiveness for manufacturers in Germany, Italy, and France who depend on overseas sales.

European equity markets have rallied despite currency headwinds. The Stoxx 600 index reached a record 583.4 points, up 0.6%. France's CAC 40 gained 0.7% and Germany's DAX rose 0.9%.

Currency strategists expect continued dollar weakness to drive further euro appreciation in coming months. The shift reverses years of dollar strength that benefited European exporters. Companies with significant US revenue exposure face translation losses when converting dollar earnings back to euros.

The forex realignment represents a cyclical shift in global currency markets, with major implications for trade flows, corporate earnings, and central bank policy across the eurozone.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score3 source documents3 with a live linkVerifiability: Strong
  1. [1]News articleUk· November 12, 2025
    Pound hits two-year low against euro as Starmer under fire
  2. [2]News articleYahoo Finance· December 31, 2025
    Stock market today: Dow, S&P 500, Nasdaq post double-digit gains in 2025 as AI trade powers market once again
  3. [3]News articleYahoo Finance· February 17, 2026
    Stock market today: Dow, S&P 500, Nasdaq waver in volatile trading as AI anxiety lingers
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com